Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug.

Antengene Corp. Ltd. (HKEX:6996) raised HK$2.8 billion via the sale of 152.2 million shares at HK$18.08, giving the company a postmoney valuation of about HK$12 billion. ...